Verve Therapeutics (VERV)

• Market cap: $556M
• 1 day: 7.00%
• 5 days: 17.53%
• 1 month: 11.36%
• 3 months: 18.38%
• 6 months: -8.50%
• Year to date: 9.32%
• 1 year: -46.97%
• 5 years: -79.42%
• 10 years: -79.42%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Employees: 255

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

28% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 47

4% more funds holding

Funds holding: 166 [Q2] → 172 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

3% less capital invested

Capital invested by funds: $383M [Q2] → $372M (-$10.8M) [Q3]

2.6% less ownership

Funds ownership: 93.41% [Q2] → 90.81% (-2.6%) [Q3]

65% less call options, than puts

Call options by funds: $414K | Put options by funds: $1.19M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 113% upside
• Avg. target: $21 220% upside
• High target: $32 387% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Whitney Ijem 18% 1-year accuracy 7 / 40 met price target	387% upside $32	Buy Maintained	6 Nov 2024
RBC Capital Luca Issi 17% 1-year accuracy 10 / 60 met price target	159% upside $17	Outperform Maintained	6 Nov 2024
HC Wainwright & Co. Mitchell Kapoor 26% 1-year accuracy 43 / 165 met price target	113% upside $14	Buy Maintained	6 Nov 2024